logo
logo
CSTL stock ticker logo

Castle Biosciences, Inc.

NASDAQ•CSTL
CEO: Mr. Derek J. Maetzold
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 2019-07-25
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Contact Information
505 South Friendswood Drive, Suite 401, Friendswood, TX, 77546, United States
866-788-9007
castlebiosciences.com
Market Cap
$816.99M
P/E (TTM)
-34.0
20.9
Dividend Yield
--
52W High
$44.28
52W Low
$14.59
52W Range
45%
Rank60Top 89.2%
2.1
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2018-2025

Financial Dashboard

Q4 2025 Data

Revenue

$87.01M+0.00%
4-Quarter Trend

EPS

-$0.08+0.00%
4-Quarter Trend

FCF

$19.75M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Net Revenue Growth Net Revenues reached $344.2M, up 3.7%, driven by strong growth in non-dermatologic test revenue streams.
Non-Derm Revenue Surge Non-Dermatologic Revenue surged $52.8M to $127.9M, largely attributed to significant TissueCypher volume increases.
Gross Margin Compression Gross Margin compressed to 69.2%, a 9.3 point decrease due to lower ASP and increased operating costs.
New Product Portfolio Expansion IDgenetix test discontinued in May 2025; AdvanceAD-Tx launched in November 2025 expanding portfolio.

Risk Factors

Financial Performance Decline Incurred net loss of $(24.2M) in 2025; sustained profitability remains uncertain due to ongoing investment needs.
Dermatologic Revenue Headwinds DecisionDx-SCC lost Medicare LCD coverage April 2025, causing $40.6M revenue decrease in dermatologic tests.
Rising Operating Costs Cost of Sales increased 18.0% to $71.0M, driven by higher personnel costs and laboratory expansion expenses.
Product Obsolescence Risk Diagnostic testing industry rapid change risks obsolescence; IDgenetix test discontinued after performance review.

Outlook

AdvanceAD-Tx Availability Expansion Plan phased expansion of AdvanceAD-Tx availability throughout 2026, targeting the estimated $33B TAM.
Continued R&D Investment Expect substantial expense increases for executing clinical studies and developing pipeline products in future periods.
Liquidity and Capital Needs Cash from operations $64.3M supports near-term needs; future growth may require equity or debt financing.
TissueCypher Technology Enhancement Acquired Previse assets to enhance TissueCypher development with new methylation-based risk stratification technology.

Peer Comparison

Revenue (TTM)

AMN stock ticker logoAMN
$2.73B
-8.5%
EVH stock ticker logoEVH
$1.88B
-26.6%
EMBC stock ticker logoEMBC
$1.08B
-2.5%

Gross Margin (Latest Quarter)

VIR stock ticker logoVIR
672.1%
-54902.1pp
ATXS stock ticker logoATXS
100.0%
+0.0pp
GERN stock ticker logoGERN
97.3%
-45.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
VIR$1.30B-3.0-49.3%18.6%
GERN$989.45M-12.1-34.3%0.0%
CDNA$964.10M-44.9-6.5%4.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-0.4%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Deep Research

Next earnings:May 4, 2026
|
EPS:-$0.24
|
Revenue:$79.10M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data